Myocardial Infarction

Pipeline Programs

Companies

Clinical Trials

1 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody

1158%

Small Molecule

632%

RNA Therapeutic

15%

Peptide

15%

+ 131 programs with unclassified modality

On Market (4)

Approved therapies currently available

JARDIANCEApproved

empagliflozin

Boehringer Ingelheim

Sodium-Glucose Cotransporter 2 Inhibitor [EPC]oral2014

8.8B Part D

BRILINTAApproved

ticagrelor

AstraZeneca

P2Y12 Platelet Inhibitor [EPC]oral2011

692M Part D

REOPROApproved

abciximab

Unknown Company

injection1994

TNKASEApproved

tenecteplase

Roche

2000

Competitive Landscape

65 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

Boehringer Ingelheim

14 programs

AlteplaseN/A1 trial

METALYSE®N/A1 trial

MetalyseN/A1 trial

Metalyse weight-adjustedN/A1 trial

coronary balloon-angioplasty with stentingN/A

+9 more programs

Active Trials

NCT02235389Terminated59

NCT02191670Completed60

NCT02206646Completed987

+8 more trials

Prevail Therapeutics

12 programs

AbciximabPhase 4Monoclonal Antibody1 trial

abciximabPhase 4Monoclonal Antibody1 trial

AbciximabPhase 3Monoclonal Antibody1 trial

Coronary AngioplastyPhase 31 trial

+7 more programs

Active Trials

NCT00136929Unknown530

NCT00149591Unknown300Est. Jan 2007

NCT00121446Completed300

+9 more trials

Medtronic

11 programs

6 months DAPTPhase 41 trial

Everolimus eluting stentPhase 41 trial

Eptifibatide facilitated PCIPhase 31 trial

Implantable Cardioverter Defibrillator + Usual CarePhase 3

PCIPhase 21 trial

+6 more programs

Active Trials

NCT02594488Completed400Est. Feb 2021

NCT02124018Completed575Est. Jul 2018

NCT05307965Completed81Est. May 2025

+7 more trials

AstraZenecaCAMBRIDGE, United Kingdom

10 programs

TicagrelorPhase 41 trial

MD-endorsed Cardiac Rehabilitation referralPhase 31 trial

Ticagrelor 90 mgPhase 31 trial

+5 more programs

Active Trials

NCT01874262Completed174Est. Dec 2014

NCT03099395Unknown100,000Est. Oct 2017

NCT00679575Completed13,171Est. Nov 2010

+7 more trials

Innovation Pharmaceuticals

4 programs

Postfibrinolysis percutaneous coronary interventionPhase 41 trial

Implantable Cardioverter Defibrillator + Usual CarePhase 31 trial

Arrhythmias in Post-Myocardial Infarction PatientsN/A1 trial

Safety of Nitroglycerin for Field Treatment of STEMIN/A

Active Trials

NCT03231826Completed445Est. Feb 2019

NCT00673842Completed700Est. Oct 2024

NCT00306228Completed436Est. Jan 2009

RocheSTAVANGER NORWAY, Norway

3 programs

Routine Early Percutaneous Coronary Intervention after ThrombolysisN/A

Spectral T Wave AlternansN/A

TNKASE(tenecteplase)PHASE_2_3

UNION therapeutics

3 programs

LevothyroxinePhase 41 trial

Bone marrow mesenchymal stem cells transferPhase 2/31 trial

AtorvastatinPhase 2Small Molecule1 trial

Active Trials

NCT03047772Unknown124Est. Dec 2018

NCT04421274Completed43Est. Jul 2011

NCT02512978Unknown160Est. Jun 2019

Boston Scientific

3 programs

rheolytic thrombectomy with direct stentingPhase 41 trial

BivalirudinPhase 31 trial

Left Atrial Appendage Closure DevicePhase 21 trial

Active Trials

NCT02492230Unknown50Est. Dec 2017

NCT00433966Completed3,602Est. Nov 2010

NCT00275990Completed501Est. Aug 2010

PfizerNEW YORK, NY

2 programs

EplerenonePhase 42 trials

Percutaneous coronary interventionPhase 4

Active Trials

NCT01971593Terminated26Est. Jun 2016

NCT01176968Completed1,012Est. Oct 2012

Sharp Therapeutics

2 programs

PrasugrelPhase 41 trial

VorapaxarPhase 41 trial

Active Trials

NCT02545933Completed130Est. Jan 2020

NCT02548650Completed66Est. Feb 2019

MSD

2 programs

PrasugrelPhase 4

VorapaxarPhase 4

ISU Abxis

1 program

ClotinabPhase 41 trial

Active Trials

NCT00841438Completed786Est. Dec 2009

Orion

1 program

HydroxychloroquinePhase 4

Orion Pharma

1 program

HydroxychloroquinePhase 41 trial

Active Trials

NCT02648464Completed125Est. Dec 2019

InspireMD

1 program

MGuardPhase 41 trial

Active Trials

NCT01368471Completed433Est. Jun 2012

Sandoz

2 programs

AliskirenPhase 31 trial

Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI PatientsN/ARNA Therapeutic1 trial

Active Trials

NCT07142265Recruiting300Est. Sep 2027

NCT00414609Completed820Est. Jul 2011

Ferrer

2 programs

Cardiovascular PolypillPhase 31 trial

FDCPhase 31 trial

Active Trials

NCT02596126Completed2,499Est. Mar 2022

NCT01321255Completed2,118Est. Jun 2014

JW Pharmaceutical

1 program

NicorandilPhase 31 trial

Active Trials

NCT02449070Unknown86Est. Oct 2018

BayerLEVERKUSEN, Germany

2 programs

FulacimstatPhase 2Small Molecule1 trial

MagnevistPhase 21 trial

Active Trials

NCT02976467Completed107Est. Sep 2018

NCT00310544Completed73Est. Sep 2006

Quantum Genomics

1 program

RamiprilPhase 2Small Molecule1 trial

Active Trials

NCT03715998Completed295Est. Jul 2021

Nyrada

1 program

XolatrypPhase 21 trial

Active Trials

NCT07362446Recruiting300Est. Sep 2027

ViiV Healthcare

2 programs

Lovaza®Phase 1/2

OPTAMI (Optimized Therapy of Acute Myocardial Infarction) - RegistryN/A

Serpin Pharma

1 program

SP16Phase 1/21 trial

Active Trials

NCT04225533Completed10Est. Dec 2021

Ventrix

1 program

VentriGelPhase 11 trial

Active Trials

NCT02305602Completed15Est. Jun 2019

RegeneRx Biopharmaceuticals

1 program

thymosin beta 4Phase 11 trial

Active Trials

NCT00743769Withdrawn0Est. Jan 2017

Eli Lilly and CompanyINDIANAPOLIS, IN

5 programs

coronary balloon-angioplasty with stentingN/A

tenecteplasePHASE_2_3

AbciximabPHASE_3Monoclonal Antibody

Coronary AngioplastyPHASE_3

fibrinolytic therapy or combination reduced fibrinolytic therapyPHASE_3

Rhythm Pharmaceuticals

4 programs

Medtronic Reveal LINQ implantable cardiac monitorN/A

T Wave Alternans TestN/A

PCIPHASE_2

GE HealthCare

3 programs

Arrhythmias in Post-Myocardial Infarction PatientsN/A

Spectral T Wave AlternansN/A

Implantable Cardioverter Defibrillator + Usual CarePHASE_3

BiotronikGermany - Berlin

3 programs

BioMonitorN/A1 trial

Implantable Cardio DefibrillatorN/A1 trial

Coronary AngioplastyPHASE_3

Active Trials

NCT02341534Completed802Est. Nov 2021

NCT01422174Withdrawn0Est. Jan 2015

PhilipsNetherlands - Amsterdam

3 programs

CTN/A2 trials

TelemetryN/A1 trial

CoolingPHASE_2_31 trial

Active Trials

NCT07619404Not Yet Recruiting220Est. Dec 2026

NCT00285064Completed20Est. May 2008

NCT02441582Completed19Est. Oct 2017

+1 more trials

+35 more companies

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

2028

2029

RegeneronAlirocumab

Boehringer IngelheimTenecteplase

AstraZenecaTicagrelor

Sharp TherapeuticsVorapaxar

Sharp TherapeuticsPrasugrel

Orion PharmaHydroxychloroquine

UNION therapeuticsLevothyroxine

AstraZenecaTicagrelor

T-TherapeuticsDanhong Injection

PfizerEplerenone

Medtronic6 months DAPT

AstraZenecaTicagrelor

Vera TherapeuticsCYP2C19 genotyping

InspireMDMGuard

PfizerEplerenone

Showing 15 of 49 trials with date data

Clinical Trials (50)

Total enrollment: 63,797 patients across 50 trials

NCT03750760 RegeneronAlirocumab

Early Alirocumab to Reduce LDL-C in Myocardial Infarction

Start: Jan 2020Est. completion: Dec 20210

Phase 4Withdrawn

NCT02777580 Boehringer IngelheimTenecteplase

STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction

Start: Aug 2017Est. completion: Sep 2023609 patients

Phase 4Completed

NCT02663713 AstraZenecaTicagrelor

A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor to Clopidogrel in Patients With Prior Myocardial Infarction

Start: Jan 2017Est. completion: Jun 201720 patients

Phase 4Completed

NCT02548650 Sharp TherapeuticsVorapaxar

Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus

Start: Mar 2016Est. completion: Feb 201966 patients

Phase 4Completed

NCT02545933 Sharp TherapeuticsPrasugrel

Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor

Start: Feb 2016Est. completion: Jan 2020130 patients

Phase 4Completed

NCT02648464 Orion PharmaHydroxychloroquine

Hydroxychloroquine for the Prevention of Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial

Start: Feb 2016Est. completion: Dec 2019125 patients

Phase 4Completed

NCT02512978 UNION therapeuticsLevothyroxine

Thyroid Hormone Replacement for Hypothyroidism and Acute Myocardial Infarction(ThyroHeart-AMI)

Start: Aug 2015Est. completion: Jun 2019160 patients

Phase 4Unknown

NCT02233790 AstraZenecaTicagrelor

Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI

Start: Dec 2014Est. completion: Dec 2016600 patients

Phase 4Unknown

NCT02158559 T-TherapeuticsDanhong Injection

the Effect of Danhong Injection on Microcirculation in the Treatment of Patients With STEMI After the PTCA Surgery.

Start: Mar 2014

Phase 4Unknown

NCT01971593 PfizerEplerenone

The Effects of Eplerenone on Markers of Myocardial Fibrosis in Adult Congenital Heart Disease

Start: Aug 2013Est. completion: Jun 201626 patients

Phase 4Terminated

NCT01459627 Medtronic6 months DAPT

Randomized, Open Label Trial of 6 Months Versus 12 Months DAPT After Drug-Eluting Stent in STEMI

Start: Dec 2011Est. completion: Aug 20171,100 patients

Phase 4Completed

NCT01347580 AstraZenecaTicagrelor

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Start: Sep 2011Est. completion: Nov 20131,875 patients

Phase 4Completed

NCT01761786 Vera TherapeuticsCYP2C19 genotyping

Cost-effectiveness of Genotype Guided Treatment With Antiplatelet Drugs in STEMI Patients: Optimization of Treatment (POPular Genetics)

Start: Jun 2011Est. completion: Apr 2019

Phase 4Completed

NCT01368471 InspireMDMGuard

Safety and Efficacy Study of MGuard Stent After a Heart Attack

Start: Jun 2011Est. completion: Jun 2012433 patients

Phase 4Completed

NCT01176968 PfizerEplerenone

Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction

Start: Sep 2010Est. completion: Oct 20121,012 patients

Phase 4Completed

NCT01347554 MedtronicEverolimus eluting stent

Efficacy of Everolimus-Eluting Versus Zotarolimus-Eluting Sten for Coronary Lesions in Acute Myocardial Infarction

Start: Jan 2009Est. completion: Mar 2013461 patients

Phase 4Completed

NCT00841438 ISU AbxisClotinab

Efficacy of Early Administration of Clotinab in Acute Myocardial Infarction

Start: Jul 2007Est. completion: Dec 2009786 patients

Phase 4Completed

NCT00440895 Prevail TherapeuticsAbciximab

A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI and Rescue-PCI

Start: Feb 2007Est. completion: May 201374 patients

Phase 4Completed

NCT00440778 Prevail TherapeuticsAbciximab

A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI

Start: Feb 2007Est. completion: Oct 2008105 patients

Phase 4Completed

NCT00422565 CordisEndeavor, Medtronic

Zotarolimus-Versus Sirolimus-Versus PacliTaxel-Eluting Stent for Acute Myocardial Infarction Patients

Start: Oct 2006Est. completion: Sep 2008328 patients

Phase 4Terminated

NCT00354406 Prevail Therapeuticsabciximab

Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty

Start: Apr 2006Est. completion: Dec 2008110 patients

Phase 4Completed

NCT00275990 Boston Scientificrheolytic thrombectomy with direct stenting

AngioJET Thrombectomy and STENTing for Treatment of Acute Myocardial Infarction

Start: Dec 2005Est. completion: Aug 2010501 patients

Phase 4Completed

NCT00162331 Lantheus Medical ImagingTechnetium Tc99m Sestamibi

CARDIOLITE-413: A Study for Patients Who Had a PCI for an Acute MI

Start: Jan 2005Est. completion: Jul 200774 patients

Phase 4Completed

NCT00138034 SanofiPercutaneous coronary intervention

APRICOT-3: Antithrombotics in the Prevention of Reocclusion In COronary Thrombolysis -3

Start: Jan 2005Est. completion: Feb 201049 patients

Phase 4Completed

NCT00306228 Innovation PharmaceuticalsPostfibrinolysis percutaneous coronary intervention

Role of Tirofiban and the Paclitaxel Eluting Stent in Postfibrinolysis Angioplasty

Start: Oct 2004Est. completion: Jan 2009436 patients

Phase 4Completed

NCT00168792 GenentechTenecteplase

A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI)

Start: Nov 20031,671 patients

Phase 4Terminated

NCT01245725 MedicureTirofiban

Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention

Phase 3Withdrawn

NCT07301034 Novo NordiskZiltivekimab

A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack

Start: Dec 2025Est. completion: Feb 2029332 patients

Phase 3Recruiting

NCT04509674 Prevail TherapeuticsEmpagliflozin

EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

Start: Dec 2020Est. completion: Nov 20236,522 patients

Phase 3Completed

NCT02596126 FerrerCardiovascular Polypill

Secondary Prevention of Cardiovascular Disease in the Elderly Trial

Start: Jul 2016Est. completion: Mar 20222,499 patients

Phase 3Completed

NCT02449070 JW PharmaceuticalNicorandil

Effects of Nicorandil on Cardiac Infarct Size in Patients With ST-segment Elevation Acute Myocardial Infarction

Start: May 2015Est. completion: Oct 201886 patients

Phase 3Unknown

NCT01321255 FerrerFDC

Fixed Dose Combination Drug (Polypill)for Secondary Cardiovascular Prevention.

Start: Jan 2012Est. completion: Jun 20142,118 patients

Phase 3Completed

NCT01327534 Daiichi SankyoPrasugrel

Early Thienopyridine Treatment to Improve Primary PCI in Patients With Acute MI

Start: May 2011Est. completion: Jul 201363 patients

Phase 3Completed

NCT00673842 Innovation PharmaceuticalsImplantable Cardioverter Defibrillator + Usual Care

Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction

Start: Apr 2011Est. completion: Oct 2024700 patients

Phase 3Completed

NCT01225562 AstraZenecaTicagrelor 90 mg

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Start: Oct 2010Est. completion: Dec 201421,379 patients

Phase 3Completed

NCT00623623 Boehringer Ingelheimprimary PCI

STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction

Start: Mar 2008Est. completion: Sep 20121,899 patients

Phase 3Completed

NCT00414609 SandozAliskiren

Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)

Start: Dec 2006Est. completion: Jul 2011820 patients

Phase 3Completed

NCT00251823 MedtronicEptifibatide facilitated PCI

Safety and Efficacy Study of Eptifibatide in Primary Percutaneous Coronary Intervention (PCI)

Start: Jul 2005Est. completion: Sep 2008400 patients

Phase 3Completed

NCT00433966 Boston ScientificBivalirudin

Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction

Start: Mar 2005Est. completion: Nov 20103,602 patients

Phase 3Completed

NCT00638638 Prevail TherapeuticsAbciximab

Myocardial Infarction With ST-Elevation

Start: Jan 2005Est. completion: Jan 2010292 patients

Phase 3Unknown

NCT00279175 Prevail TherapeuticsIntracoronary infusion of enriched bone marrow-derived progenitor cells

REPAIR-AMI: Intracoronary Progenitor Cells in Acute Myocardial Infarction (AMI)

Start: Apr 2004Est. completion: Dec 2010204 patients

Phase 3Completed

NCT00220571 Prevail TherapeuticsCoronary Angioplasty

CARESS in Acute Myocardial Infarction

Start: May 2003Est. completion: Mar 2007600 patients

Phase 3Completed

NCT00336830 AstraZenecaMD-endorsed Cardiac Rehabilitation referral

Improving Cardiac Rehabilitation Participation in Women and Men

Start: May 2003Est. completion: Dec 20091,035 patients

Phase 3Completed

NCT00046228 Prevail Therapeuticsabciximab placebo; reteplase placebo, abciximab, abciximab

A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)

Start: Aug 2002Est. completion: Jan 20082,461 patients

Phase 3Completed

NCT00245648 Prevail Therapeuticsfibrinolytic therapy or combination reduced fibrinolytic therapy

Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI

Start: Jun 2001Est. completion: Oct 2007

Phase 3Completed

NCT00148460 Boehringer IngelheimTNK-tPA

Trial to Compare the Efficacy and Safety of a Single Bolus of TNK-tPA (Tenecteplase, Metalyse®) With Accelerated Infusion of Rt-PA (Alteplase, Actilyse®) in Asian Patients With Acute Myocardial Infarction

Start: Mar 2001Est. completion: Feb 2006270 patients

Phase 3Completed

NCT02181998 Boehringer IngelheimFull dose tenecteplase

A Trial on Efficacy and Safety of Full Dose Tenecteplase Combined With Unfractionated Heparin (UFH) or Enoxaparin in Acute Myocardial Infarction (AMI) in the Prehospital Setting

Start: Jul 20001,606 patients

Phase 3Completed

NCT02182011 Boehringer IngelheimTenecteplase

A Study to Investigate the Procoagulant Effect of Tenecteplase (TNK-tPA), Alteplase (Rt-PA) and Streptokinase (SK) Administered to Patients With Acute Myocardial Infarction (AMI)

Start: May 200049 patients

Phase 3Completed

NCT02181985 Boehringer IngelheimFull dose TNK-tPA

Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)

Start: May 20005,989 patients

Phase 3Completed

NCT01379261 PhilipsCooling

Efficacy of Endovascular Catheter Cooling Combined With Cold Saline for the Treatment of Acute Myocardial Infarction

Start: Jun 2011Est. completion: Nov 2013120 patients

Phase 2/3Completed

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

16 late-stage (Phase 3) programs, potential near-term approvals

1 actively recruiting trials targeting 63,797 patients

30 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.